Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced new